Antidiabetic preparation for oral administration

Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Tablets – lozenges – or pills

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C424S464000, C424S465000, C424S468000, C424S469000, C424S484000

Reexamination Certificate

active

07488498

ABSTRACT:
There is provided a single preparation which directly decreases both of the post prandial blood glucose level and the fasting blood glucose level close to normal levels, by release-sustaining a drug capable of decreasing the post prandial blood glucose level of diabetic patients close to the normal level, or mixing a controlled release drug capable of decreasing the post prandial blood glucose level close to the normal level with an immediate release drug. It is particularly preferable that the drug capable of decreasing the post prandial blood glucose level close to the normal level is nateglinide.

REFERENCES:
patent: 5296236 (1994-03-01), Santus et al.
patent: 5609884 (1997-03-01), Desai
patent: 6004582 (1999-12-01), Faour et al.
patent: 6056977 (2000-05-01), Bhagwat et al.
patent: 6143323 (2000-11-01), Yabuki et al.
patent: 6197348 (2001-03-01), Morella et al.
patent: 6296872 (2001-10-01), Yabuki et al.
patent: 6414126 (2002-07-01), Ellsworth et al.
patent: 6559188 (2003-05-01), Gatlin et al.
patent: 6638535 (2003-10-01), Lemmens et al.
patent: 6641841 (2003-11-01), Yabuki et al.
patent: 6830759 (2004-12-01), Makino et al.
patent: 6844008 (2005-01-01), Yabuki et al.
patent: 7022339 (2006-04-01), Makino et al.
patent: 2003/0077297 (2003-04-01), Chen et al.
patent: 2003/0124191 (2003-07-01), Besse et al.
patent: 2004/0014815 (2004-01-01), Ninomiya et al.
patent: 2004/0029968 (2004-02-01), Ninomiya et al.
patent: 2006/0029669 (2006-02-01), Makino et al.
patent: 0 793 959 (1997-09-01), None
patent: 0 965 339 (1999-12-01), None
patent: 10-231242 (1998-09-01), None
patent: 11-130696 (1999-05-01), None
patent: 11-139960 (1999-05-01), None
patent: 2001-2583 (2001-01-01), None
patent: WO 94/05277 (1994-03-01), None
patent: WO 98/02105 (1998-01-01), None
patent: WO 98/56378 (1998-12-01), None
patent: WO 01/21159 (2001-03-01), None
patent: WO 01/47557 (2001-07-01), None
Journal of Clinical and Experimental Medicine, Jan. 30, 1999, vol. 188, No. 5, pp. 518-521.
Starlix, , Novartis Package Insert, DJN 608/Nateglinide, Jan. 4, 2001, pp. 1-12.
Doctors Guide Global Edition, FDA Approves Starlix (Nateglinide) for Type Diabetes, Dec. 27, 2000, pp. 1-3.
Diabetes Center, Department of Internal Medicine, University of Munich, Germany, Record 7, Meglitinide analogues in the treatment of type 2 diabetes mellitus, (Abstract) Drugs Aging, vol. 17, Issue 5.
Web address: http//www.home.eznet.net/˜webtent/repaglinide.html, Repaglinide (Prandin), printed on Jun. 24, 2002.
Carol Lewis, Diabetes: A Growing Public Health Concern, U.S. Food and Drug Administration, FDA Consumer Magazine, Jan.-Feb. 2002.
U.S. Food and Drug Administration, FDA Consumer Magazine, Oral Antidiabetes Medications, Jan.-Feb. 2002.
A. Bakkali-Nadi, et al., “Insulinotroopic Action of Meglitinide Analogs: Concentration-Response Relationship and Nutrient Dependency”, Diabetes Research, 1994, 27, pp. 81-87.
B. Luna, et al., “Oral Agents in the Management of Type 2 Diabetes Mellitus”, American Family Physician, May 1, 2001, vol. 63, No. 9, pp. 1747-1756.
U.S. Appl. No. 11/349,225, filed Feb. 8, 2006, Makino et al.
U.S. Appl. No. 11/246,453, filed Oct. 11, 2005, Makino et al.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Antidiabetic preparation for oral administration does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antidiabetic preparation for oral administration, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antidiabetic preparation for oral administration will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-4137534

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.